EOD 3.3 #125
Merged
EOD 3.3 #125
Conversation
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
|
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment
Add this suggestion to a batch that can be applied as a single commit.
This suggestion is invalid because no changes were made to the code.
Suggestions cannot be applied while the pull request is closed.
Suggestions cannot be applied while viewing a subset of changes.
Only one suggestion per line can be applied in a batch.
Add this suggestion to a batch that can be applied as a single commit.
Applying suggestions on deleted lines is not supported.
You must change the existing code in this line in order to create a valid suggestion.
Outdated suggestions cannot be applied.
This suggestion has been applied or marked resolved.
Suggestions cannot be applied from pending reviews.
Suggestions cannot be applied on multi-line comments.
Suggestions cannot be applied while the pull request is queued to merge.
Suggestion cannot be applied right now. Please check back later.
EOD v3.3 Review and Conversion:
After EOD v3.3 has been deployed
If your registry captures/calculates Derived EOD 2018 fields:
A) If Date of Diagnosis Year is 2018 or later and Schema ID [3800] = 00580
Recalculate the Derived EOD 2018 Stage Group
B) If Date of Diagnosis Year is 2018 or later and Schema ID [3800] = 00580 and Derived EOD 2018 Stage Group [818] = 1, 2A, 3A
If Derived Summary Grade [1975] = 9, A, B, C, D, E or is blank,
Set Derived EOD 2018 Stage Group = 99
Else if PSA Lab Value [3920] = XXX.2, XXX.3, XXX.7, XXX.9
Set Derived EOD 2018 Stage Group = 99
No other changes are necessary. No manual review is necessary.
(This can always be applied. Calculation tables were updated. No review necessary.)
EOD v3.3 known issues:
EOD v3.3 changes:
EOD and SS2018
- includes changes to schema definitions, EOD fields and SS2018
General Changes
Version 9 Updated Diseases: AJCC released the 9th revision of the 2 diseases which will be effective for cases diagnosed 1/1/2026 or after. There are now 2 schemas for each. Also, the Oropharynx schemas were renamed to align with the new terminology.
Major Salivary Glands [8th: 2018-2025], Schema ID [#3800] = 00080
Major Salivary Glands [V9: 2026+], Schema ID [#3800] = 09081
Oropharynx HPV-Associated [8th: 2018-2025], Schema ID [#3800] = 00100
Oropharynx HPV-Associated [V9: 2026+], Schema ID [#3800] = 09100
Sex Assigned At Birth [225]: Sex was used for the schema selection of Primary Peritoneal Carcinoma, Retroperitoneum, Soft Tissue Other, Soft Tissue Rare. NAACCR is discontinuing Sex [220] and adding Sex Assigned at Birth [225]. For additional details, see the schema notes below.
Type of Reporting Source [500] was added as a field to all schema in preparation of more robust default value logic. Similar to Primary Site [400], this is solely to make the field available for calculations and no change in how it is collected or presented is necessary.
Behavior ICDO3 [523] was added to all schemas that did not already have it where SS2018 = 0 (In situ) is valid in preparation of more robust default value logic
RX Summ Surgery/Radiation Sequence [1380], RX Summ Systemic/Surgery Sequence [1639] were removed from all schema except Prostate, as they are not used in the calculations in EOD 2018.
Derived EOD 2018 T, N, M and Stage Group fields [785, 815, 795, 818] will no longer be calculated or available in the public SEER EOD 2018 Staging tools. By agreement between NCI and AJCC, these fields are not supposed to be available or used in the facilities and are solely a central registry feature. If you are a vendor supporting a central registry that uses the Derived EOD 2018 fields, please let Nicki Schussler ([email protected]) know as soon as possible so the appropriate support can be provided.
Appendix, Appendix V9
EOD Regional Nodes [774]: Note 3 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Regional Nodes Positive [820]: Default set to 99 to align with all other schemas
Bile Ducts Distal, Bile Ducts Perihilar, Cystic Duct, Gallbladder
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection.
Breast
EOD Primary Tumor [772]: Note 2 modified to indicate it relates to clinical evidence descriptions only. Code 450 is scheduled for removal, please use code 400 moving forward; Code 700 is scheduled for removal, please use code 600 moving forward. Codes 450 and 700 modified to indicate they are obsolete; there is no conversion at this time. Code 500 modified to specify WITHOUT inflammatory carcinoma and remove code 450
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Buccal Mucosa, Floor of Mouth, Gum, Lip, Mouth Other, Palate Hard, Tongue Anterior, Cutaneous Carcinoma of Head and Neck
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Colon and Rectum
EOD Regional Nodes [774]: Note 3 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Esophagus, Esophagus Squamous
EOD Regional Nodes [774]: Note 3 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
HemeRetic
Schema: Note 3 modified to add histologies that apply in 2023+; Note 6 modified to update WHO manual reference and adjust text of several histologies
EOD Primary Tumor [772]: Note 1 added referencing the 2024 WHO manual; corrected text description of Histology 9982
Summary Stage 2018 [764]: added reference to the 2024 WHO manual; Note 3 modified to add histologies that apply in 2023+; Note 4 modified to remove Site exceptions and add acronyms and a note about 9971; Note 6 modified to adjust text of several histologies; Code 1 and Code 7 modified to indicate the correct Note reference
Hypopharynx, Larynx Glottic, Larynx Subglottic, Larynx Supraglottic, Larynx Other
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Larynx SupraGlottic
Schema Definition: for Date of Diagnosis Year 2026 and later, all Primary Site [400] = C101 with Histology ICD-O-3 [522] = 8000-8700 will be assigned to Oropharynx schemas
Summary Stage 2018 [764]: Notes introduction modified to show C101 logic only applies to diagnosis year 2018-2025
Lung
EOD Primary Tumor [772]: Code 500 modified to add Azgos vein and Stellate ganglion and thoracic nerve roots and remove Brachial plexus inferior branches or NOS; Code 650 modified to remove Azygos vein and Stellate ganglion and to add Brachial vein, Supra-aortic arteries, Brachial plexus, Subclavian vessels and Thymus
Lymphoma
Schema: Note 3 modified to add histologies that apply in 2023+; Note 5 modified to update text for histologies
Lymphoma, Lymphoma CLL/SLL
Summary Stage 2018 [764]: Note 3 modified to add histologies that apply in 2023+; Note 4 modified to update WHO manual reference and update text for histologies
Lymphoma Ocular Adnexa
Schema: Note 3 modified to include histology list;
Summary Stage 2018 [764]: Note 5 added with histology list
Major Salivary Glands 8th, Major Salivary Glands V9
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Maxillary Sinus, Nasal Cavity & Ethmoid Sinus
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Nasopharynx V9
Schema Selection: for Date of Diagnosis Year 2025 and later, all Primary Site [400] = C111 with Histology ICD-O-3 [522] = 8000-8700 will be assigned to Nasopharynx, and Schema Discriminator 1 [3926] will no longer be associated with Nasopharynx V9. Schema Selection rules streamlined accordingly
Schema Notes modified to include all C111 in this schema and remove references to Schema Discriminator 1 and Oropharynx schemas
Schema Discriminator 1 [3926]: removed from the schema
Nasopharynx 8th, Nasopharynx V9
Summary Stage 2018 [764]: Notes introduction modified to show C111 logic differs in 2018-2024
Oropharynx HPV-Mediated (p16+)
Scheme renamed as 'Oropharynx HPV-Associated [8th: 2018-2025]'
Schema Selection: for Date of Diagnosis Year 2025 and later, all Primary Site [400] = C111 with Histology ICD-O-3 [522] = 8000-8700 will be assigned to Nasopharynx, and Schema Discriminator 1 [3926] will only be applied to cancers with Date of Diagnosis Year 2024 and prior. All other selections are limited to 2018-2025 for the addition of the V9 schema. (See 'EOD v3.3 Review and Conversion')
Schema Notes modified to reflect that C111 only is assigned to Oropharyx in 2018-2024; Schema Notes modified to reflect new names of Oropharynx schemas
Oropharynx (p16-)
Scheme renamed as 'Oropharynx HPV-Independent'
Schema Selection: for Date of Diagnosis Year 2025 and later, all Primary Site [400] = C111 with Histology ICD-O-3 [522] = 8000-8700 will be assigned to Nasopharynx, and Schema Discriminator 1 [3926] will only be applied to cancers with Date of Diagnosis Year 2024 and prior. (See 'EOD v3.3 Review and Conversion'); for Date of Diagnosis Year 2026 and later, Primary Site [400] = C101 with Histology ICD-O-3 [522] = 8000-8700 and Schema Discriminator 2 = 1, 9 will be assigned to Oropharynx HPV-Independent
Schema Notes modified to reflect that C111 only is assigned to Oropharyx in 2018-2024; Schema Notes modified to reflect new names of Oropharynx schemas
Oropharynx HPV-Associated 8th, HPV-Associated V9, Oropharynx HPV-Independent
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Summary Stage 2018 [764]: Notes introduction modified to show C111 logic only applies to diagnosis year 2018-2024 and to add C101 for diagnosis year 2026 and later
Pancreas, Stomach
EOD Regional Nodes [774]: Note 4 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Plasma Cell Disorders
EOD Primary Tumor [772]: Notes 1 and 2 modified to specify single tumor; Note 4 modified to update the WHO manual reference
Plasma Cell Disorders, Plasma Cell Myeloma
Summary Stage 2018 [764]: added reference to the 2024 WHO manual; histology text modified
Primary Cutaneous Lymphoma
Summary Stage 2018 [764]: Note 4 modified to update WHO manual reference and update the histology text
Primary Peritoneal Carcinoma, Retroperitoneum
Schema Selection: NAACCR is discontinuing Sex [220] and adding Sex Assigned at Birth [225]. Schema selection for Primary Peritoneal Carcinoma modified to include Sex Assigned at Birth = 2 and Schema selection for Retroperitoneum modified to include Sex Assigned at Birth = 1, 9
Small Intestine
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
Soft Tissue Other, Soft Tissue Rare
Schema Selection: NAACCR is discontinuing Sex [220] and adding Sex Assigned at Birth [225]. While the previous definition of Sex, if Sex = 4 for C481-C482, C488 with 8806, 8930-8931, the cancer was assigned to Soft Tissue Other. These patients will now have Sex Assigned at Birth = 9 and will be assigned to Soft Tissue Rare. (See 'EOD v3.3 Review and Conversion')
Testis
EOD Regional Nodes [774]: Note 2 modified to clarify when Clinical codes vs Pathological codes should be used with respect to surgical resection
SSDI and Grade
- NAACCR is the custodian of these fields, changes are listed here for convenience. See Change Log on https://apps.naaccr.org/ssdi/list/ for complete information.
General
The SSDI manual is now being created from an extraction from the API. Several formatting changes were made in text fields to ensure a consistent look and feel within the resulting word document.
Bile Duct Intrahepatic, Liver
Fibrosis Score [3835]: added the end year 2023 to the SEER RC requirement as SEER is no longer collecting this field
Bone Appendicular Skeleton, Bone Pelvis, Bone Spine
Percent Necrosis Post Neoadjuvant [3908]: added the end year 2025 as this SSDI is no longer required by any standard setter; SEER (RC) end year set to 2023
Breast
HER2 Overall Summary [3255]: Note 7 modified to streamline the instructions
Residual Cancer Burden [1178]: added as a new SSDI; required by CoC and SEER (RC) for 2026 forward
Residual Cancer Burden Class [1179]: added as a new SSDI; required by CoC and SEER (RC) for 2026 forward
Multigene Signature Method [3894], Multigene Signature Result [3895]: added the end year 2023 to the SEER requirement as SEER is no longer collecting these fields
Oncotype DX Risk Level DCIS [3905], Oncotype DX Risk Level Invasive [3906]: added the end year 2025 as this SSDI is no longer required by any standard setter; SEER (RC) end year set to 2023.
Oncotype DX Risk Level Invasive [3906]: Chemotherapy was added to the end of the Description for High Risk
Oncotype DX Recurrence Score-DCIS [3903]: added the end year 2023 to the SEER (RC) requirement as SEER is no longer collecting this field
Buccal Mucosa and all Head & Neck
Extranodal Extension Head and Neck Clinical [3831], Extranodal Extension Head and Neck Pathological [3832]: To streamline both maintenance and the manual, these schemas will all use the same two validation table and notes for these SSDIs. Additional Information text was modified for both Source Documents and Other Names
Extranodal Extension Head and Neck Clinical [3831]: Note 2 modified to include additional information about sources and indications of ENE; Coding Guidelines 1-4 modified for readability; Coding Guideline 6 for Code 9 final bullet removed – LN biopsy performed and is negative for ENE or not state; Code 1 modified for readability
Extranodal Extension Head and Neck Pathological [3832]: Note 2 modified to include additional information about sources and indications of ENE; Note 3 added, this was split from Note 2 for regional vs distant; Note 4 added to clarify minor vs major ENE; Coding Guidelines 9 first bullet modified to move the explanation into Note 2; changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
Buccal Mucosa and all H&N, Cutaneous Carcinoma of Head and Neck
LN Size [3883]: To streamline both maintenance and the manual, these schemas will all use the same validation table and notes for this SSDI. Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck Code 0 for LN Size will thus contain 'Non-invasive neoplasm (behavior /2)'; Note 2 added to describe the criteria for coding LN Size; Note 3 modified to add more clarity on the use of clinical or pathological size; Coding Guidelines 1 modified to specify the size is in millimeters; changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility (For Oropharynx HPV-Associated 8th, LN Size is part of the calculation and will be required through 2025)
Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck, Melanoma Head and Neck
LN Head and Neck Levels I-III [3876], LN Head and Neck Levels IV-V [3877], LN Head and Neck Levels IV-VII [3878], LN Head and Neck Other [3879]: To streamline both maintenance and the manual, both schemas will use the same validation table and notes for these SSDIs. Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck code 0 for these fields will thus contain 'Non-invasive neoplasm (behavior /2)'; changed SEER requirement to SEER (RC) for 2024 forward, these will only be required by SEER if the cancer is reported by a CoC facility
Cervical Lymph Nodes and Unknown Primary Tumor of Head and Neck
Schema Discriminator 1 [3926]: Notes and code meanings were adjusted for the Nasopharynx V9 schema and the Oropharynx schemas name change and V9 addition
Cervix 8th, Cervix V9, Cervix Sarcoma, Corpus Adenosarcoma, Corpus Carcinoma & Carcinosarcoma, Corpus Sarcoma, Fallopian Tube, Ovary, Placenta, Primary Peritoneal Carcinoma, Vagina, Vulva 8th, Vulva V9
FIGO Stage [3836]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
Cervix 8th, Cervix V9, Vagina, Vulva 8th, Vulva V9
LN Status: Pelvic [3957]: Coding Guidelines 1.c. modified to replace 'femoral-inguinal' replaced with 'pelvic' both times it appeared; SEER requirement corrected to be SEER (RC)
Cervix 8th, Cervix V9, Vagina
LN Status: Para-aortic [3958]: Coding Guidelines 1.c. modified to replace 'femoral-inguinal' replaced with 'para-aortic' both times it appeared; SEER requirement corrected to be SEER (RC)
Colon and Rectum
Tumor Deposits [3934]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
KRAS [3866]: in the Coding Guidelines, the 3rd sub-bullet in # 4 about Codon 146 was removed; this was an accidental repeat of # 5.
Corpus Carcinoma and Carcinosarcoma
Microsatellite Instability (MSI) [3890]: added as a new SSDI for this schema; required by CoC and SEER (RC) for 2026 forward
Cutaneous Carcinoma of Head and Neck
High Risk Histologic Features [3858]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
Fallopian Tube, Ovary, Primary Peritoneal Carcinoma
Residual Tumor Volume Post Cytoreduction [3921]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
GIST
KIT Gene Immunohistochemistry [3865]: added Note 2 describing the types of results that can be used to code field.
Heart, Mediastinum, and Pleura; Retroperitoneum; Soft Tissues Abdomen and Thoracic; Soft Tissues Head and Neck; Soft Tissues Trunk and Extremities; Soft Tissue Rare; Soft Tissue Other
Bone Invasion [3815]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
HemeRetic
JAK2 [3862]: Additional Information modified to limit the Source Documents to clinical lab tests.
Kidney Parenchyma
Ipsilateral Adrenal Gland Involvement [3861], Invasion Beyond Capsule [3864], Major Vein Involvement [3886]: changed SEER requirement to SEER (RC) for 2024 forward, these will only be required by SEER if the cancer is reported by a CoC facility
Lacrimal Gland
Adenoid Cystic Basaloid Pattern [3803]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
Lung V9
Spread Through Air Spaces (STAS) [1176]: added as a new SSDI; required by CoC and SEER (RC) for 2026 forward
PD-L1 [1174]: Note 5 was added to describe the limited way in which Combined Proportion Score can be used
Lung 8th, Lung V9
Separate Tumor Nodules [3929], Visceral and Parietal Pleural Invasion [3937]: changed SEER requirement to SEER (RC) for 2024 forward, these will only be required by SEER if the cancer is reported by a CoC facility
Lymphoma; Lymphoma CLL/SLL
NCCN International Prognostic Index (IPI) [3896]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
HIV Status [3859]: added the end year 2023 to the SEER requirement as SEER is no longer collecting this field
Melanoma Choroid and Ciliary Body; Melanoma Iris
Chromosome 3 Status [3821], Chromosome 8q Status [3822], Extravascular Matrix Pattern [3834], Microvascular Density [3891]: added the end year 2023 to the SEER (RC) Requirement as SEER is no longer collecting these fields
Melanoma Skin
Clinical Width Margin [3961]: Note 1 modified to specify field is for C44x cancers only and all others should use XX.9; changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
LDH Lab Value [3932]: changed SEER requirement to SEER (RC) for 2024 forward, this will only be required by SEER if the cancer is reported by a CoC facility
Merkel Cell Skin
LN Isolated Tumor Cells (ITC) [3880], Profound Immune Suppression [3918]: changed SEER requirement to SEER (RC) for 2024 forward, these will only be required by SEER if the cancer is reported by a CoC facility
Nasopharynx [8th: 2018-2024], Oropharynx HPV-Associated [8th: 2018-2025], Oropharynx HPV-Independent
Schema Discriminator 1 [3926]: Notes modified to reflect the new names for the Oropharynx schemas and to limit this discriminator to diagnosis years 2018-2024; Validation table modified to remove Nasopharynx V9 as the discriminator is not needed for that schema, and that the Discriminator should be blank for 2025 and later
Schema Discriminator 2 [3927]: Description modified to include the new names for the Oropharynx schemas; additional information is provided regarding how to determine HPV status; Notes modified to reflect the new names for the Oropharynx schemas; Note 2 modified to expand what types of test can be considered and to specify how different results scenarios should be coded; Validation table modified to adjust the Oropharynx schema names and IDs
NET Schemas
Grade Clinical [3843], Grade Pathological [3844], Grade Post Therapy Clin [1068], Grade Post Therapy Path [3845]: Note 4/5 modified to add explanation of when codes A-D can be used; Note 5/6 added to specify terminology that cannot be used to code Grade; Note 6/7 added to describe what information can be used to code grade, starting with physician’s statement.
Plasma Cell Myeloma
High-risk Cytogenetics [3857]: Note 2 added to indicate this SSDI is a component of R-ISS and how to code if only R-ISS stage is given
LDH Level [3869]: Note 3 modified to indicate this SSDI is a component of R-ISS and how to code if only R-ISS stage is given
Serum Albumin Pretreatment Level [3930]: Additional Information Source Documents modified to provide a more complete list of sources; Note 2 sub-bullet modified to specify which test results can be used; Note 3 sub-bullet added to describe how to code if only R-ISS stage is given
Serum Beta-2 Microglobulin Pretreatment Level [3931]: Note 3 modified to indicate this SSDI is a component of R-ISS and how to code if only R-ISS stage is given
Prostate
PSA Lab Value [3920]: Note 3 added to specify how performance diagnostic biopsy affection collection of PSA Lab Value with examples as this is a change in the rules; Coding Guidelines 1 sub-bullets removed as they are covered by Note 3
Number of Cores Positive [3898], Number of Cores Examined [3897]: Note 4 added to define how to code targeted or region of interest biopsies
Gleason Tertiary Pattern [3842]: changed SEER requirement be SEER for 2018-2023 and SEER (RC) for 2024 forward, moving forward, this will only be required by SEER if the cancer is reported by a CoC facility
Testis
AFP Pre-Orchiectomy Range [3808], AFP Post-Orchiectomy Range [3806], hCG Pre-Orchiectomy Range [3849], hCG Post-Orchiectomy Range [3847], LDH Pre-Orchiectomy Range [3868], LDH Post-Orchiectomy Range [3867]: changed SEER requirement to SEER (RC) for 2024 forward, these will only be required by SEER if the cancer is reported by a CoC facility
Vagina, Vulva 8th, Vulva V9
LN Status: Femoral-Inguinal [3959]: SEER requirement corrected to be SEER (RC)
Vulva 8th, Vulva V9
EOD Master ONLY